Investing.comDoubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 18:04:33·⟳ 抓取 18:05:38 +1m05s·⚡ 决策 10-20 18:16:26 +10m48s·7.0 天前
Rapport Therapeutics 宣布 RAP-219 治疗急性双相躁狂 II 期试验达到主要及次要终点，盘前一度飙涨约40%
真实阳性临床读出但属于低质量阳性：p=0.045仅勉强过线、安慰剂校正效应3.1分偏小、单一试验、III期要到2027H2才启动，距收入兑现极远；盘前已在真实重定价约+40%（$28.6→$40），此时追入的剩余edge被统计边际与见光死风险大幅侵蚀，风险收益比不佳。
📄 原文Investing.com↗ 原文
Rapport reports positive phase 2 trial results for RAP-219
BOSTON and SAN DIEGO - Rapport Therapeutics Inc. (NASDAQ:RAPP) announced today that its Phase 2 trial of RAP-219 in adu…
不做 Rapport Therapeutics, Inc.（RAPP.US）
盘前已真实重定价约+40%（$28.6→$40），而读出为低质量阳性（p=0.045勉强过线、效应3.1分、单一II期、III期一年后才启动），追高的剩余edge被边际统计与开盘见光死/高开低走风险侵蚀，风险收益比不足；无可核实的跨市场映射标的。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RAP-219双相躁狂II期达到主/次要终点且安全性良好，消除了一项适应症层面的临床风险；但p值仅0.045、效应量小、III期在一年后，盘前已大涨约40%，追高风险收益比不足，故不做。
消息传播链
- 节点
- 节点
关键理由
- 公司100%拥有RAP-219，双相躁狂为癫痫之外的第二适应症阳性验证，现金4.36亿美元可支撑至2029H2，短期无融资压力
- 盘前约+40%的涨幅已在实时消化该利好，且p=0.045的边际统计与3.1分小效应容易在开盘后被分析师质疑
主要风险
- 临床读出仅单一II期、p值勉强显著，III期2027H2才启动，若完整数据或FDA沟通要求额外试验则逻辑证伪
- 盘前低成交量（约3.1万股）下的+40%价格发现不充分，开盘可能高开低走
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
主要终点p=0.045仅勉强显著、安慰剂校正效应3.1分偏小、III期2027H2才启动；盘前已+40%，统计强度不足以支撑追高，削弱做多edge
检索:RAP-219 bipolar mania phase 2 p=0.045 criticism analyst sell-the-news 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加盘前已+40%，是最终选择不追高、不给出ENTER的重要原因之一
方向:本轮未取得锚点干净的同市场II期神经/精神科读出先例面板，无法据外部基率先验判断+40%缺口后的胜率
涨幅量级:无高相似aligned先例，不能据此设定可靠的tp/sl幅度
形态:小型biotech边际阳性（p≈0.045）读出常见高开后分歧，但本轮无真实日线上的先例面板支撑量化
工具执行结果 · 成功 6 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`rapp rap-219 253 patients ymrs primary endpoint | rapport therapeutics phase 2 acute bipolar mania endpoints met | rapport therapeutics rap-219 phase 2 bipolar mania results`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - stock_quote 成功 stock_tools HTTP · 508 ms
{ - web_search 成功 doubao_search · 1,848 ms
豆包搜索结果（原始查询:Rapport Therapeutics RAP-219 phase 2 bipolar mania results press release；API SearchType:web） - kb_search 失败 stock_tools HTTP · 60 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,504 ms
豆包搜索结果（原始查询:Rapport Therapeutics RAP-219 bipolar mania Phase 2 topline October 20 2026；API SearchType:web） - web_search 成功 doubao_search · 1,858 ms
豆包搜索结果（原始查询:RAPP stock RAP-219 phase 2 bipolar mania analyst reaction p=0.045；API SearchType:web）
原文全文
展开原文 · 1,989 字
BOSTON and SAN DIEGO - Rapport Therapeutics Inc. (NASDAQ:RAPP) announced today that its Phase 2 trial of RAP-219 in adults with acute bipolar mania met its primary and secondary endpoints, according to a press release statement.
The trial enrolled 253 adults with bipolar I disorder experiencing an acute manic episode in the United States. Patients received 0.75 mg of RAP-219 once daily or placebo for three weeks in an inpatient setting.
RAP-219 achieved a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale total score at Week 3, with a mean reduction from baseline of 15.4 points compared to 12.3 points with placebo (p=0.045). The mean baseline YMRS total score was 36.9 in the RAP-219 arm and 35.8 in the placebo arm.
The trial also met its secondary endpoint, with RAP-219 demonstrating a 0.4-point improvement in the Clinical Global Impression-Bipolar Version mania severity scale versus placebo at Week 3 (p=0.024).
All 11 items measured by the YMRS improved numerically compared to placebo at Week 3, with improvements in irritability, thought content, disruptive-aggressive behavior, and sexual interest reaching nominal significance.
During the three-week treatment period, the incidence of treatment-emergent adverse events was similar between RAP-219 and placebo at 51.6% versus 52.8%. All TEAEs were mild or moderate in severity, with no serious adverse events observed. The discontinuation rate due to TEAEs was 3.2% for RAP-219 compared with 0.8% for placebo.
The company plans to meet with the FDA in the first quarter of 2027 to discuss Phase 2 data and registrational trial design. Initiation of two Phase 3 trials in acute bipolar mania is expected in the second half of 2027.
As of June 30, 2026, Rapport had $436.1 million in cash, cash equivalents and short-term investments, expected to fund operations into the second half of 2029.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The trial enrolled 253 adults with bipolar I disorder experiencing an acute manic episode in the United States. Patients received 0.75 mg of RAP-219 once daily or placebo for three weeks in an inpatient setting.
RAP-219 achieved a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale total score at Week 3, with a mean reduction from baseline of 15.4 points compared to 12.3 points with placebo (p=0.045). The mean baseline YMRS total score was 36.9 in the RAP-219 arm and 35.8 in the placebo arm.
The trial also met its secondary endpoint, with RAP-219 demonstrating a 0.4-point improvement in the Clinical Global Impression-Bipolar Version mania severity scale versus placebo at Week 3 (p=0.024).
All 11 items measured by the YMRS improved numerically compared to placebo at Week 3, with improvements in irritability, thought content, disruptive-aggressive behavior, and sexual interest reaching nominal significance.
During the three-week treatment period, the incidence of treatment-emergent adverse events was similar between RAP-219 and placebo at 51.6% versus 52.8%. All TEAEs were mild or moderate in severity, with no serious adverse events observed. The discontinuation rate due to TEAEs was 3.2% for RAP-219 compared with 0.8% for placebo.
The company plans to meet with the FDA in the first quarter of 2027 to discuss Phase 2 data and registrational trial design. Initiation of two Phase 3 trials in acute bipolar mania is expected in the second half of 2027.
As of June 30, 2026, Rapport had $436.1 million in cash, cash equivalents and short-term investments, expected to fund operations into the second half of 2029.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6140de9774· 2026-10-20 18:16 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前